Home
Lars Andreas Akslen's picture

Lars Andreas Akslen

Professor, Centre Director of CCBIO
  • E-mailLars.Akslen@uib.no
  • Phone+47 55 97 31 82
  • Visitor Address
    Dept. of Pathology, Sentralblokka 2nd floor, Haukeland University Hospital (HUH)
    or CCBIO, Sentralblokka 2nd floor, Haukeland University Hospital (HUH)
  • Postal Address
    Postboks 7804
    5020 Bergen

Akslen is a certified specialist in surgical pathology and is directing the Tumor Biology Research Group (since the establishment in 1995) at Department of Clinical Medicine (University of Bergen). Since 2013, Akslen is the director of Centre for Cancer Biomarkers CCBIO. Akslen´s team, and now CCBIO, are engaged in translational cancer research with a strong focus on  exploration and validation of novel biomarkers for more biologically based classification and grading of malignant tumors, as a better guide for targeted treatment. The group has included projects on various cancers, such as breast cancer, malignant melanoma, prostate cancer, and gynecologic cancers. Studies of human tumor samples are combined with experimental cell and animal models to improve translation. The overall aim is to provide novel biomarkers which can assist in prediction of aggressive tumor behavior and be helpful in tailored treatment.

Academic article
  • Show author(s) 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLOS ONE. 14 pages.
  • Show author(s) 2008. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma research. 29-35.
  • Show author(s) 2008. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. International Journal of Oncology. 307-316.
  • Show author(s) 2008. Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS - Journal of Pathologiy, Microbiology and Immunology. 515-525.
  • Show author(s) 2007. ERG upregulation and related ETS transcription factors in prostate cancer. International Journal of Oncology. 19-32.
  • Show author(s) 2006. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Research. 3303-3309.
  • Show author(s) 2006. Role of angiogenesis in human tumor dormancy - Animal models of the angiogenic switch. Cell Cycle. 1779-1787.
  • Show author(s) 2006. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. American Journal of Obstetrics and Gynecology. 979-986.
  • Show author(s) 2006. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical 14 retropubic prostatectomy for localized prostate cancer? BJU International. 51-55.
  • Show author(s) 2006. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 161-175.
  • Show author(s) 2006. Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Archiv. 68-74.
  • Show author(s) 2006. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology. 268-273.
  • Show author(s) 2005. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. Journal of Urology. 425-428.
  • Show author(s) 2005. Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. International Journal of Oncology. 329-336.
  • Show author(s) 2005. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. Journal of Investigative Dermatology. 312-317.
  • Show author(s) 2004. The prognostic implication of the basal-like (cyclin E-high/p27(low)/p53(+)/glomeruloid-microvascular-proliferation(+)) phenotype of BRCA1-related breast cancer. Cancer Research. 830-835.
  • Show author(s) 2004. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. International Journal of Oncology. 1615-1623.
  • Show author(s) 2004. Prognostic impact of histological grade and vascular invasion compared with tumor cell proliferation in endometrial carcinoma of endometrioid type. Histopathology. 472-479.
  • Show author(s) 2004. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. Journal of Clinical Oncology. 1242-1252.
  • Show author(s) 2004. Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. International Journal of Gynecological Cancer. 957-965.
  • Show author(s) 2004. Karnydanning og tumorkar som mål for kreftterapi. Tidsskrift for Den norske legeforening. 1919-1922.
  • Show author(s) 2004. Immunohistochemical and Clinical Characterization of the Basal-like Subtype of Invasive Breast Carcinoma. Clinical Cancer Research. 5367-5374.
  • Show author(s) 2004. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. International Journal of Oncology. 1559-1565.
  • Show author(s) 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • Show author(s) 2003. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1011-1018.
  • Show author(s) 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • Show author(s) 2003. Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecologic Oncology. 218-25.
  • Show author(s) 2003. MSI-low, a real phenomenon which varies in frequency among cancer types. Journal of Pathology. 389-94.
  • Show author(s) 2003. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute. 1482-85.
  • Show author(s) 2003. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clinical Cancer Research. 1474-1479.
  • Show author(s) 2003. Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: a prospective study of 510 patients. Urology. 447-450.
  • Show author(s) 2002. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 673-689.
  • Show author(s) 2002. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research. 138-43.
  • Show author(s) 2002. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. 2185-91.
  • Show author(s) 2002. Can we rely on pathologic parameters to define conservative treatment of papillary thyroid carcinoma? International Journal of Surgical Pathology. 267-272.
  • Show author(s) 2001. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Research. 7 pages.
  • Show author(s) 2001. Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiology, Biomarkers and Prevention. 113-117.
  • Show author(s) 2001. Expression of oestrogen and progesterone receptorss, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African poplation. East African Medical Journal. 360-5.
  • Show author(s) 2001. Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. Oncogene. 885-892.
  • Show author(s) 2000. Molecular portraits of human breast tumours. Nature. 747-52.
  • Show author(s) 2000. Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans. Anticancer Research. 4857-62.
  • Show author(s) 1999. The PTEN gene is methylated in endometrial carcinoma and associated with advanced disease and microsattelite instability. (Abs. no. 207). American Journal of Human Genetics. S. 209.
  • Show author(s) 1999. TP53 as a predictor of response to chemotherpy in breast cancer. RSO Scientific Updates. 73-88.
  • Show author(s) 1999. TP53 as a predictor of response to chemotherapy in breast cancer. European School of Oncology Scientific Updates. 73-88.
  • Show author(s) 1999. Strong prognostic influence of reduced p16 protein expression in endometrial carcinomas. A large population based study. (Abstract no. 0-079). Virchows Archiv. 185.
  • Show author(s) 1999. Significance of tumor associated macrophages. VEGF and TSP-1 expression for tumor angiogenesis and prognosis in endometrial carcinomas. International Journal of Cancer. 539-543.
  • Show author(s) 1999. Significance of tumor associated macrophages, VEGF and TSP-1 for angiogenesis and prognosis of endometrial carcinoma. International Journal of Cancer. 538-43.
  • Show author(s) 1999. Prognostic value of tumor angiogenesis, Ki67, p53 and p21 protein expression - a population based endometrial carcinoma study. Journal of Clinical Oncology. 595-99.
  • Show author(s) 1999. Prognostic significance of tumor angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. Journal of Clinical Oncology. 1382-1390.
  • Show author(s) 1999. Prognostic significance of angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. International Journal of Oncology. 395-399.
  • Show author(s) 1999. Loss of nuclear expression of p16 protein correlates with increased tumor cell proliferation and poor patient outcome in patients with vertical growth phase melanoma. (Abstract no. P-487). Virchows Archiv. 314.
  • Show author(s) 1999. Influence of TP53 gene alterations and Her-2 expression on the respons to treatment with doxorubicin in locally advanced breast cancer. (Abs. no. 227). Breast Cancer Research and Treatment.
  • Show author(s) 1999. Enhanced expression of EGF-receptor and low frequency of ras mutations in X-ray-induced rat thyroid tumours. Virchows Archiv. 434-441.
  • Show author(s) 1999. Clinicopathological characteristics of melanomas of the hand. Journal of Hand Surgery - British and European Volume. 460-64.
  • Show author(s) 1999. Clinicopathological characteristics of melanomas of the hand. Journal of Hand Surgery - British and European Volume. 460-64.
  • Show author(s) 1999. Angiogenesis is prognostically important in vertical growth phase melanomas. International Journal of Oncology. 595-599.
  • Show author(s) 1998. Økt forekomst av kreft i skjoldkjertelen blant norske kvinner gift med fiskere. Tidsskrift for Den norske legeforening. 4202-4205.
  • Show author(s) 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • Show author(s) 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • Show author(s) 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • Show author(s) 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • Show author(s) 1998. Prognostic impact of morphometric nuclear grade in endometrial carcinoma. Cancer. 956-964.
  • Show author(s) 1998. Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
  • Show author(s) 1998. Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
  • Show author(s) 1998. Identification of high-risk patients by assessment of nuclear Ki67 expression in a prosepective study of endometrial carcinoma patients. Clinical Cancer Research. 2779-2785.
  • Show author(s) 1998. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. International Journal of Cancer. 91-95.
  • Show author(s) 1998. Diagnostisk molekylærbiologi ved solide svulster: Thyreoideacancer. Tidsskrift for Den norske legeforening. 2199-2203.
  • Show author(s) 1998. Diagnostisk molekylærbiologi ved solide svulster - thyreoidea. Tidsskrift for Den norske legeforening. 2199-2203.
  • Show author(s) 1998. Decreased survival for nulliparous women with endometrial carcinoma. Is the relationship due to biology or behaviour? Cancer. 1328-1333.
  • Show author(s) 1997. Recurrent endometrial carcinoma and the value of routine follow-up. British Journal of Obstetrics and Gynaecology. 1302-1307.
  • Show author(s) 1997. Recurrence of endometrial carcinoma and the value of routine follow up. British Journal of Obstetrics and Gynaecology. 1302-1307.
  • Show author(s) 1997. Recurrence of endometrial carcinoma and the value of routine follow up. British Journal of Obstetrics and Gynaecology. 1302-1307.
  • Show author(s) 1997. Prognostisk betydning av tumorbiologiske markører ved kreft i livmorslimhinnen. Kreftnytt. 4-7.
  • Show author(s) 1997. Increased risk of thyroid cancer among Norwegian females married to fishery workers. British Journal of Cancer. 385-389.
  • Show author(s) 1997. Expression of p16 protein in prostatic adenocarcinomas, intraepithelial neoplasia and benign/hyperplastic glands. Urologic Oncology. 59-66.
  • Show author(s) 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Show author(s) 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Show author(s) 1997. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. International Journal of Cancer. 535-540.
  • Show author(s) 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Show author(s) 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Show author(s) 1997. Absence of p21 Expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Show author(s) 1996. Thyroid carcinomas with tall-cell and columnar-cell features (letter). Current Diagnostic Pathology. 67.
  • Show author(s) 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Show author(s) 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Show author(s) 1996. Relationship between mutations in the TP53 gene and De Novo resistance and early relapse following treatment with doxorubicin in patients with breast cancer. Nature Medicine. 811-814.
  • Show author(s) 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Show author(s) 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Show author(s) 1996. Primary organ-culture of non neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Show author(s) 1996. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer. 1211-1219.
  • Show author(s) 1996. Incidence of thyroid cancer in New Caledonia, South Pacific, during 1985-1992 (letter). American Journal of Epidemiology. 1174.
  • Show author(s) 1996. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Research. 1184-1188.
  • Show author(s) 1996. Cytoplasmatic localization of EGF receptor in papillary thyroid carcinomas: Association with the 150-kDa receptor forms. International Journal of Cancer. 161-167.
  • Show author(s) 1996. Aggressive thyroid carcinoma with predominant cribriform growth pattern. Pathology, Research and Practice.
  • Show author(s) 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Show author(s) 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Show author(s) 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Show author(s) 1995. Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor (EGF-R), c-erbB-2 protein, estrogen receptor related protein (p29), p21-ras protein and proliferation indicators in relation to tumor recurrences and patients survival. Cancer. 1643-1654.
  • Show author(s) 1995. Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor (EGF-R), c-erbB-2 protein, estrogen receptor related protein (29), p21-ras protein and proliferation indicators in relation to tumor recurrences and patient survival. Cancer. 1643-1654.
  • Show author(s) 1995. Lack of diagnostic value of DNA content and p53 immunostaining in normal, hyperplastic and neoplastic parathyroid tissue. Oncology Reports. 69-72.
  • Show author(s) 1995. Histopatologiens betydning for vurdering av kreftforekomst og kreftårsaker. Tidsskrift for Den norske legeforening. 943-946.
  • Show author(s) 1994. Thyroid cancer: some aspects of epidemiology and etiological factors, pathological features and tumour biology. International Journal of Oncology. 931-942.
  • Show author(s) 1994. Ploidy and proliferative rates in carcinomas of the breast in Tanzania. East African Medical Journal. 195-198.
  • Show author(s) 1994. Ploidy and proliferative rates in carcinomas of the breast in Tanzania. East African Medical Journal. 195-198.
  • Show author(s) 1994. Kreft i skjoldbruskkjertelen - økning i yngre årskull. Kreftnytt. 4-6.
  • Show author(s) 1994. Increase of endo-and exo-peptidases in thyroid tumors. Oncol Rep. 953-956.
  • Show author(s) 1994. Increase of endo- and exo-peptidases in thyroid tumours. Oncol Rep. 953-956.
  • Show author(s) 1994. Increase of endo- and exo-peptidases in thyroid tumors. Oncol Rep. 953-956.
  • Show author(s) 1994. Etiologiske og patobiologiske aspekter ved malignt melanom. Tidsskrift for Den norske legeforening. 908-911.
  • Show author(s) 1993. Thyroid cancer in children in Norway 1953-1987. European Journal of Cancer. 365-366.
  • Show author(s) 1993. Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. European Journal of Cancer. 44-51.
  • Show author(s) 1993. Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. European Journal of Cancer. 44-51.
  • Show author(s) 1993. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 2680-2685.
  • Show author(s) 1993. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. British Journal of Cancer. 808-812.
  • Show author(s) 1993. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. British Journal of Cancer. 808-812.
  • Show author(s) 1993. Incidence pattern of thyroid cancer in Norway: influence of birth cohort and time period. International Journal of Cancer. 183-187.
  • Show author(s) 1993. Demonstration of a TGF-_a-EGF receptor autocrine loop and c-myc protein overexpression in papillary thyroid carcinomas. International Journal of Cancer. 37-43.
  • Show author(s) 1992. Thyroid carcinoma. Results from surgical treatment in 211 consecutive patients. European Journal of Surgery. 521-526.
  • Show author(s) 1992. Second malignancies in thyroid cancer patients: a population-based survey of 3658 cases from Norway. European Journal of Cancer. 491-495.
  • Show author(s) 1992. Reproductive factors and risk of thyroid cancer. A prospective study of 63090 women from Norway. British Journal of Cancer. 772-774.
  • Show author(s) 1992. Expression of p53 protein in cutaneous melanoma. International Journal of Cancer. 13-16.
  • Show author(s) 1992. Expression of c-erbB-2 protein in papillary thyroid carcinomas. British Journal of Cancer. 832-837.
  • Show author(s) 1992. Disease free and cause specific survival in patients with papillary thyroid carcinoma. A multifactorial analysis. European Journal of Surgery. 583-589.
  • Show author(s) 1992. Differentiated thyroid carcinomas: the relevance of various pathological features for tumour classification and prediction of tumour progress. Virchows Archiv. A, Pathological anatomy and histopathology. 17-23.
  • Show author(s) 1991. Thyroid carcinoma: Results from surgical treatment in 211consecutive patients. European Journal of Surgery. 521-526.
  • Show author(s) 1991. Thyroid carcinoma. Results from a uniform surgical strategy 1971-1985. Acta Chirurgica Scandinavica. 521-526.
  • Show author(s) 1991. Survival and cause of death in thyroid cancer: A population-based study of 2479 cases from Norway. Cancer Research. 1234-1241.
  • Show author(s) 1991. Squamous cell carcinoma of the urinary bladder. Scandinavian Journal of Urology and Nephrology. 275-276.
  • Show author(s) 1991. Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. British Journal of Urology. 61-69.
  • Show author(s) 1991. Periodicity in metastatic tumour growth demonstrated in human liver at autopsy. Invasion Metastasis. 58-64.
  • Show author(s) 1990. Provocation of thyroid neoplasms in female Wistar rats fed n-3 or n-6 fatty acids in the feed. Thyroidology. 1-3.
  • Show author(s) 1990. Increased content of chronium and nickel in lung tissues patients with bronchial carcinoma. Pathology, Research and Practice. 717-722.
  • Show author(s) 1989. Lifestyle and mortality among Norwegian men. Preventive Medicine. 433-443.
  • Show author(s) 1988. Life-style and caridovascular mortality among Norwegian men (Abstract). Circulation. 479.
Academic lecture
  • Show author(s) 2016. Molecular subtypes of breast cancer: long-term incidence trends and prognostic differences.
  • Show author(s) 2016. FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
  • Show author(s) 2013. Molekylære subtyper og overlevelse ved brystkreft.
  • Show author(s) 2013. Molekylære subtyper og overlevelse ved brystkreft.
  • Show author(s) 2012. Multimodal imaging for suspected recurrent differentiated thyroid cancer (DTC): FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
  • Show author(s) 2011. Multimodal imaging for diagnosis and treatment of recurrent differentiated thyroid cancer (DTC)FDG-PET-CT, contrast-enhanced CT (CE-CT), I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
  • Show author(s) 2011. In vivo Dynamic Contrast Enhanced MRI & Histopathological Assessment of Tumor Angiogenesis in Luminal-like and Basal-like Breast Cancer Xenografts.
  • Show author(s) 2011. FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB) for recurrent differentiated thyroid cancer (DTC).
  • Show author(s) 2011. Early vascular response to bevacizumab treatment measured by DCE-MRI in breast cancer xenografts.
  • Show author(s) 2011. DCE-MRI for early therapy monitoring of anti-angiogenic therapy.
  • Show author(s) 2010. Real time elastografi ved cancer prostatae.
  • Show author(s) 2010. Preliminære resultater av PCA3 måling i urin hos pasienter med cancer prostatae.
  • Show author(s) 2010. Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound.
  • Show author(s) 2010. In vivo magnetic resonance imaging and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.
  • Show author(s) 2010. Er preoperativ MR-prostata nyttig for å avklare korrekt T-stadium forut for kirurgi?
  • Show author(s) 2010. Er MR-prostata nyttig for å avklare videre oppfølgningsbehov hos pasienter med 2 eller flere negative biopsiserier?
  • Show author(s) 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • Show author(s) 2009. EMT Promotes Malignant Transformation of Prostate Epithelial Cells in Culture.
  • Show author(s) 2008. Polycomb group target genes and bivalent H3K4 & K27me3 modifications in human embryonic cells were enriched among dysregulated genes in prostate cancer.
  • Show author(s) 2008. Epithelial to mesenchymal transition of a primary, immortalized prostate cell line is associated with gene expression switches of entire cell attachment modules.
  • Show author(s) 2007. Functional oncogenomics and epigenomics analysis of prostate cancer.
  • Show author(s) 2007. Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients and identification of ERG target genes.
  • Show author(s) 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines.
  • Show author(s) 2006. ERG upregulation and related transcription factors in prostate cancer.
  • Show author(s) 2004. Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
  • Show author(s) 2004. Gene expression profiles in prostate cancer: identification of upregulated SIM2 gene validated in archival tissue, relation to histological grading and prognosis.
  • Show author(s) 2003. Mutation analysis of the RAS-RAF pathway in pancreatic adenocarcinomas and malignant melanomas.
  • Show author(s) 2003. Global analysis of gene expression and regulatory patterns in urogenital tumours using DNA microarrays.
  • Show author(s) 2003. Global analysis of gene expression and regulatory patterns in cancer.
  • Show author(s) 2003. Gene expression profiling in prostate cancer: cluster analysis and association with tumor differentation.
  • Show author(s) 2003. Gene expression profiling in prostate cancer: Cluster analysis and association with tumor differentiation.
  • Show author(s) 2003. Gene expression profiling in prostate cancer.
  • Show author(s) 2003. DNA microarray studies of human cancer - pitfalls and outlook.
  • Show author(s) 2003. Comparison of DNA microarray and real time quantitative PCR for quantitation of gene expression of selected genes in prostate cancer.
  • Show author(s) 2002. Cancer mammae behandlet med brystbevarende kirurgi ved Haukeland sykehus 1984-1995.
  • Show author(s) 2001. Prognostisk betydning av angiogenese (microvessel density - MVD) og proliferasjonsmarkøren Ki-67 ved lokalisert prostatacencer.
  • Show author(s) 1999. Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
  • Show author(s) 1998. Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
  • Show author(s) 1998. Profylaktisk thyroidectomi hos barn - initial erfaring.
  • Show author(s) 1998. Malignt melanom på hender.
  • Show author(s) 1998. Malignant melanoma of the hand. A 25-year clinico-pathological study.
  • Show author(s) 1997. Independent prognostic importance of microvessel density in endometrial carcinoma. [poster].
  • Show author(s) 1989. Mortality form ischemic heart disease related to life-style differences among Norwegian men (Abstract).
Academic anthology/Conference proceedings
  • Show author(s) 2017. Biomarkers of the Tumor Microenvironment: Basic Studies and Practical Applications. Springer.
Abstract
  • Show author(s) 2013. Proliferation markers PHH3, Ki67 and mitotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Modern Pathology. 50A-50A.
  • Show author(s) 2013. Proliferation markers PHH3, Ki67 and Mimtotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Laboratory Investigation. 50A-50A.
  • Show author(s) 2013. FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 pages.
  • Show author(s) 2012. Prognostic impact of proliferation markers Ki-67, PHH3 and mitotic count in breast carcinomas. Virchows Archiv. S5-S5.
  • Show author(s) 2012. Metabolic Responses to VEGF Inhibition in Patient-derived Breast Cancer Xenografts. European Journal of Cancer. S32-S32.
  • Show author(s) 2012. Expression of hypoxia-inducible factor-1a and associations with vascular endothelial growth factor expression, high microvessel density and features of aggressive tumors in African breast cancer. Virchows Archiv. S249-S249.
  • Show author(s) 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • Show author(s) 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • Show author(s) 2010. Prognostic importance of vascular proliferation and tumor cell invasion in blood and lymphatic vessels in endometrial carcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 248-248.
  • Show author(s) 2010. Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound [Abstract]. European Journal of Nuclear Medicine and Molecular Imaging. S291-S291.
  • Show author(s) 2009. Proliferation of immature tumor vessels is a novel marker of clinical progress in prostate cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 233-233.
  • Show author(s) 2008. Vascular proliferation by Nestin/Ki-67 is a novel predictor of the clinical progress of prostate cancer. Histopathology. 276-277.
  • Show author(s) 2008. Candidate stem cell marker ALDH1 expression and relationship with BRCA-mutations and basal-like differentiation in breast carcinoma. Histopathology. 25-25.
  • Show author(s) 2007. Loss of BMI-1 expression is associated with the clinical progress of malignant melanoma. Virchows Archiv. 452-452.
  • Show author(s) 2007. Epithelial to mesenchymal transition is of strong prognostic importance in prostate cancer. Virchows Archiv. 344-344.
  • Show author(s) 2007. Basal-like phenotype is frequent in invasive breast carcinoma from Ugandan Africans and is strongly associated with a high expression of EGFR/c-Kit and features of aggressive tumors. Virchows Archiv. 137-137.
  • Show author(s) 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines. International Journal of Molecular Medicine. S27.
  • Show author(s) 2006. ERG upregulation in relation to other transcription factors in prostate cancer. NBS-nytt. 72.
  • Show author(s) 2005. Single-minded 2 homolog gene is overexpressed in prostate cancer. Virchows Archiv. 432-432.
  • Show author(s) 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer. International Journal of Molecular Medicine. S76-S76.
Academic literature review
  • Show author(s) 2013. Malignt melanom – diagnostikk, behandling og oppfølging i Norge. Tidsskrift for Den norske legeforening. 2154-2159.
  • Show author(s) 2009. Biologic markers in endometrial cancer treatment. APMIS - Journal of Pathologiy, Microbiology and Immunology. 693-707.
  • Show author(s) 2008. Tumor-vascular interactions and tumor dormancy. APMIS - Journal of Pathologiy, Microbiology and Immunology. 569-585.

More information in national current research information system (CRIStin)